OGN: Organon & Co. Stock

by  •  • Comments Off on OGN: Organon & Co. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3,833.14
Enterprise Value ($M) 12,038.14
Book Value ($M) 493.00
Book Value / Share 1.91
Price / Book 7.78
NCAV ($M) -8,281.00
NCAV / Share -32.10
Price / NCAV -0.46

Profitability (mra)
Return on Invested Capital (ROIC) 0.09
Return on Assets (ROA) 0.07
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.11
Current Ratio 1.60

Balance Sheet (mrq) ($M)
Current Assets 4,348.00
Assets 13,101.00
Liabilities 12,629.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 6,403.00
Operating Income 1,708.00
Net Income 864.00

Cash Flow Statement (mra) ($M)
Cash From Operations 939.00
Cash from Investing -513.00
Cash from Financing -368.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
2024-02-13 13G/A Vanguard Group Inc 11.97 -2.78

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2024-11-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 780,212 3,313,612 23.55
2025-03-06 567,659 1,937,937 29.29
2025-03-05 907,846 2,474,767 36.68
2025-03-04 904,997 3,096,729 29.22

(click for more detail)

Similar Companies
LLY – Eli Lilly and Company MRK – Merck & Co., Inc.
NUVB – Nuvation Bio Inc. PBH – Prestige Consumer Healthcare Inc.
PFE – Pfizer Inc.


Financial data and stock pages provided by
Fintel.io